N
Naoto T. Ueno
Researcher at University of Texas MD Anderson Cancer Center
Publications - 390
Citations - 13778
Naoto T. Ueno is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Inflammatory breast cancer. The author has an hindex of 59, co-authored 389 publications receiving 11623 citations. Previous affiliations of Naoto T. Ueno include University of Texas Health Science Center at Houston & The Breast Cancer Research Foundation.
Papers
More filters
Journal ArticleDOI
Nonmyeloablative Allogeneic Hematopoietic Transplantation: A Promising Salvage Therapy for Patients With Non-Hodgkin's Lymphoma Whose Disease Has Failed a Prior Autologous Transplantation
Maricer P. Escalon,Richard E. Champlin,Rima M. Saliba,Sandra Acholonu,Chitra Hosing,Luis Fayad,Sergio Giralt,Naoto T. Ueno,Farzaneh Maadani,Barbara Pro,Michele L. Donato,Peter McLaughlin,Issa F. Khouri +12 more
TL;DR: Data suggest that nonmyeloablative allogeneic stem-cell transplantation is an effective option in lymphoma patients with chemosensitive or stable disease who experience disease recurrence following autologous transplantation.
Journal ArticleDOI
Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation
Raymond S.M. Wong,Munir Shahjahan,Xuemei Wang,Peter F. Thall,Marcos de Lima,Issa F. Khouri,James Gajewski,J. Alamo,Daniel R. Couriel,Borje S. Andersson,M. Donato,Chitra Hosing,Krishna V. Komanduri,Paolo Anderlini,Jeffrey J. Molldrem,Naoto T. Ueno,Elihu H. Estey,Cindy Ippoliti,Richard E. Champlin,Sergio Giralt +19 more
TL;DR: The data support the use of allogeneic transplantation for patients with relapsed or refractory acute myelogenous leukemia/myelodysplastic syndromes and suggest that optimal immune suppression early after transplantation is essential for long-term survival even in patients withRefractory myeloid leukemias.
Journal ArticleDOI
Histone Deacetylase Inhibitors Stimulate Dedifferentiation of Human Breast Cancer Cells Through WNT/β‐Catenin Signaling
Bisrat G. Debeb,Lara Lacerda,Wei Xu,Richard A. Larson,Travis Solley,Rachel L. Atkinson,Erik P. Sulman,Naoto T. Ueno,Savitri Krishnamurthy,James M. Reuben,Thomas A. Buchholz,Wendy A. Woodward +11 more
TL;DR: It is demonstrated thatHDAC inhibitors promote the expansion of breast CSCs through dedifferentiation and have important clinical implications for the use of HDAC inhibitors in the treatment of cancer.
Journal ArticleDOI
Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer
Takeo Fujii,Takahiro Kogawa,Wenli Dong,Aysegul A. Sahin,S. L. Moulder,Jennifer K. Litton,Debu Tripathy,Takayuki Iwamoto,K. K. Hunt,Lajos Pusztai,Bora Lim,Yu Shen,Naoto T. Ueno +12 more
TL;DR: Stage II or III HER2-negative primary breast cancer with ER < 10% behaves clinically like triple-negative breast cancer in terms of pCR and survival outcomes and patients with such tumors may have a limited benefit from adjuvant hormonal therapy.
Journal ArticleDOI
Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
Fanny Le Du,Bedrich L. Eckhardt,Bora Lim,Jennifer K. Litton,Stacy L. Moulder,Funda Meric-Bernstam,Ana M. Gonzalez-Angulo,Naoto T. Ueno +7 more
TL;DR: This work reviewed published TNBC molecular classifications to identify major groupings that have potential for clinical trial development and linked these categories of TNBC according to their gene-expression signatures, biological function, and clinical outcome.